Final results for the year ended 31 December 2019 and outlook for 2020

Paris, France and Camberley, UK – 14 May 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces its audited final results for the year ended 31 December 2019 and provides an outlook for 2020. http://novacyt.com/wp-content/uploads/2020/05/Novacyt-FY19-financial-results-PR-ENGLISH-14.05.2020-FINAL.pdf

Visit Page

Liquidity Agreement Monthly Update and Total Voting Rights

Paris, France and Camberley, UK – 4 May 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces its monthly update in relation to ordinary shares traded under its ongoing liquidity agreement with Invest Securities SA (the “Liquidity Agreement”). The Liquidity Agreement is governed by French law and is further

Visit Page

Coronavirus test update and notification of final results

Paris, France and Camberley, UK – 29 April 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, provides an update on its polymerase chain reaction (PCR) test for COVID-19, developed by Primerdesign, the Company’s molecular diagnostics division based in the UK. http://novacyt.com/wp-content/uploads/2020/04/Novacyt-COVID-19-test-update-and-notification-of-final-results-ENGLISH-29.04.2020.pdf

Visit Page